1. Fig. 4. LTB4 production is elevated in preclinical and clinical lymphedema.
LTB4 production is elevated in preclinical and clinical lymphedema. (A) LTB4 concentrations in the lymph fluid, measured by liquid chromatography–tandem mass spectrometry (LC-MS/MS) over time as mouse tail lymphedema developed; n = 6. (B) Mouse serum LTB4 concentrations, measured by LC-MS/MS. Blood serum was collected on postsurgical day 24; n = 6. (C) Transcripts of Ltb4r1 and Ltb4r2 in the tail skin, measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR); n = 5. (D) Quantification of 5-LO–positive macrophages in the mouse tail skin in fig. S3B; n = 5. (E) LTB4 concentrations in the blood serum of healthy controls (n = 21) and lymphedema (n = 18) patients, measured by LC-MS/MS. Demographic data are shown in table S1. (F) Quantification of 5-LO–expressing macrophages in patient skin samples in fig. S8; n = 5. For (A), (B), and (E), data are presented in box-and-whiskers plots showing minimal to maximal values and all data points; for (C), (D), and (F), data are presented as means and SEM; comparisons with day 0 samples in (A) and (C) were made using Kruskal-Wallis test followed by Dunn’s multiple comparisons test for post hoc analyses; comparisons as indicated in (B), (D), (E), and (F) used the Mann-Whitney test.
Wen Tian et al., Sci Transl Med 2017;9:eaal3920
Published by AAAS